The trial will test several treatment approaches in the maintenance setting for extensive stage small cell lung cancer.

Emerging therapies, including antibody-drug conjugates and biomarker-driven approaches, have the potential to significantly ...

Most patients demonstrated at least partial response to tarlatamab in a real-world population with extensive-stage small cell ...

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ...

IMDELLTRA is a first-in-class targeted immunotherapy engineered by Amgen. A pharmacist filling a prescription for a complex drug developed by the company.

AMGN's Imdelltra slashes lung cancer death risk by 40% in Phase III, extending survival by over five months compared to chemotherapy.

BioNTech is set to receive up to $7.6 billion in future payments based on certain milestones. (Yahoo! Finance) Amgen’s drug Imdelltra cut small cancer lung cell death risk by 40%. The drug has ...

Drugmakers unveil cancer drug data at the ASCO annual meeting, while Amazon Pharmacy announces new features for caregivers, Medicare patients.

Imdelltra also extended median overall survival by more than five months compared to the standard-of-care chemotherapy.